Immuno & targeted therapy provide new options for difficult-to-treat head&neck cancer

(European Society for Medical Oncology) Novel strategies are on the way for difficult-to-treat and advanced head and neck cancer, the most heterogeneous group of malignancies which are generally associated with poor survival, and encouraging results have been presented at the first ESMO Asia 2015 Congress in Singapore.